Cancer is the "top killer" of human health. Traditional cancer treatment methods include surgery, radiotherapy and chemotherapy, but all of them are carried out by directly killing cancer cells, which is difficult to completely remove cancer cells and cause serious damage to normal cells and tissues. Different from traditional treatments, immunotherapy destroys tumors by regulating the body's immune defense mechanism without damaging normal cells and tissues. This paper first introduces the characteristics of immunotherapy, and expounds the research status of tumor therapy based on immunotherapy from two aspects of active immunotherapy and passive immunotherapy, aiming to provide theoretical reference for tumor drug research and promote tumor immunotherapy to achieve greater breakthroughs.

Zhang Lu. Research Status of Tumor Therapy Based on Immunotherapy. Frontiers in Medical Science Research (2022) Vol. 4, Issue 2: 30-33. https://doi.org/10.25236/FMSR.2022.040206.

[1] Li Fangfang, ZHENG Shangyong. Journal of kunming university of science and technology (natural science edition), 2019, 44(05):76-83.

[2] Vormehr M, et al. Mutanome directed cancer immunotherapy [J]. Current Opinion in Immunology, 2016, 39:14 -22.

[3] Antonia S J, Larkin J, Ascierto P A. Immuno-oncology combinations: A review of clinical experience and future prospects [J].Clinical Cancer Research, 2014, 20(24):6258-6268. 

[4] Schmidli, et al. Overview of tumor immunotherapy and its mechanism of action [J]. Progress in veterinary medicine, 018, 39(07):114-118.

[5] Dmitriy Zamarin, et al. Immune checkpoint modulation: Rational design of combination strategies [J].Pharmacology and Therapeutics, 2015.

[6] Shengjie Xu, Yanan Wang, Shiyu Wang, Yuan Liu, Sufang Wu. Research status and development trend of tumor immunotherapy [J].Advances in modern, 2018, 18(15):2982-2986.

[7] Melief C,etal. Therapeutic cancer vaccines [J].Dressnature Reviews Drug Discovery, 2015, 125(9):3401.

[8] Liang Y,et al.The tumor protection effect of high-frequency administration of whole tumor cell vaccine and enhanced officacy by the protein component from agrocybe aegerita [J]. Int J Exp Med, 2015, 8(5):6914-6925.

[9] Vander Burg SH, et al. Vaccines for established cancer: overcoming the challenges posed by immune evasion [J].Nat Rev Cancer, 2016, 16(4):219-233.

[10] Clifton GT, et al. Adjuvant HER2/neupeptide cancer vaccines in breast cancer [J]. Immunotherapy, 2015, 7(11):1159-1168

[11] Clifton GT, et al. Clinnical development of the E75 vaccine in breast cancer [J]. Breast Care, 2016, 11(2):116-121.

[12] Campbell CT, et al. Humoral response to a viral glcan correlates with survival on PROSTVAC-VF [J]. Pro Natl Acad Sci USA, 2014, 111(17):E1749-E1758.

[13] Weiner GJ. Building better monoclonal antibody-based therapeutics [J]. Nat Rev Cancer, 2015, 15(6):361-370. 

[14] Sedykh SE, et al. Bispecific antibodies:design, therapy, perspectives [J].Drug Des Devel Ther, 2018,12:195-208.

[15] Kimberly D, et al. A Cancer Journal for Clinicians [J]. Cancer treatment and survivorship statistics, 2016, (4).

[16] Alena AC, et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen [J]. Clin Cancer Ｒes,2010, 16(14): 3594-3606．

[17] Cheng M, et al. NK cell-based immunetherapy for malignant diseases [J]. Cell Mol Immunol, 2013, 10(3): 230-252.

[18] Hu Y, et al. Chimeric antigen receptor（CAR）- transduced natural killer cells in tumor immunotherapy [J]. Acta Pharmacol Sin,2018,39（2):167-176.

[19] Masanori K, et al. The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer[J].J Ovarian Ｒes,2014,7:48．

[20] Koido S. Dendritic-Tumor Fusion Cell-Based Cancer Vaccines [J]. International Journal of Molecular Sciences, 2016, 17(6): 828.